Predictive parameters of arteriovenous fistula maturation in patients with end-stage renal disease by Siddiqui, Muhammad A. et al.
Introduction
Chronic kidney disease (CKD) is an important condi-
tion with considerable public health implications that 
are further multiplied by rising rates of diabetes mellitus, 
obesity, and hypertension and the aging of the popula-
tion [1]. The recorded prevalence of CKD for 2014 to 2015 
in England was 4.1 per 100 people among those aged 18 
years and older versus 3.16 per 100 people aged 18 years 
and older in Scotland [2]. A total of 58,968 adult patients 
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were reported as receiving renal replacement therapy in 
the United Kingdom (UK) at the end of 2014 for a preva-
lence of 913 per million people in the UK [3]. 
End-stage renal disease (ESRD) is a serious condition 
affecting a large part of the population and, as such, rep-
resents a considerable financial burden for the health 
sector. After kidney transplantation, dialysis is the best 
active treatment option for people with ESRD [4]. To en-
sure that dialysis therapy can be efficiently performed, all 
patients need a fully developed fistula that is appropriate 
for the process of cannulation. In order to achieve this, 
several stages have to be covered, namely, pre-ESRD 
treatment by a kidney specialist and early referral to vas-
cular surgeons for the construction, development, and 
cannulation of a fistula by a dialysis specialist. Vascular 
surgeons are required to construct mature arteriovenous 
fistulas (AVFs) so as to ensure their successful matura-
tion and proper functioning to withstand dialysis. AVFs 
are cheaper; last longer; have lower infection, morbidity, 
and mortality rates; and reduce the chances of repeat in-
tervention [5,6]. However, access problems represent the 
main determinant of morbidity among hemodialysis pa-
tients and put a considerable degree of financial pressure 
on the health care sector [3]. Asif et al [7] indicated that 
the percentage of AVFs that fail to develop sufficiently 
for dialysis is between 28% and 53%. Dialysis therapy is 
often postponed for up to half a year or more to allow for 
extra time for the fistula to develop; a fistula that fails to 
mature is a fistula that either has never matured so as to 
be useful, is difficult to cannulate, or that fails to gener-
ate the necessary blood flow (600 mL/min) for successful 
two-needle dialysis [8]. 
It may be possible to improve the end results of AVF 
by gaining a more comprehensive picture of the factors 
involved in the maturation of fistulas. In addition, such 
analysis can provide important information during the 
presurgical evaluation that surgeons can use to make 
their decisions. Independent predictive factors may be 
beneficial in anticipating the rate of fistula maturation 
without the use of invasive tests and could be cost-effec-
tive. The main purpose of the present study therefore was 
to explore the potential influence of blood markers and 
patient characteristics such as risk factors, kidney func-
tion profile, coagulation profile, lipid profile, body mass 
index (BMI), blood pressure (BP), and vein diameter on 
the maturation of AVF in patients with ESRD.
Methods
Research design
The study protocol was approved by the South East 
Scotland Research Ethics Committee 03, Edinburgh, UK 
(no. 09/S1103/29), and the favorable ethical opinion was 
obtained from the Queen Margaret University (Edin-
burgh, UK) ethics committee for the present study, which 
was performed in two stages. The development stage in-
volved the collection of retrospective data and the identi-
fication of relevant independent predictors for a predic-
tive model of fistula maturation. The second (validation) 
stage involved the validation of a development model on 
a prospective set of data from the Royal Infirmary of Ed-
inburgh.
Development stage 
Using the retrospective clinical database of patients 
with ESRD, researchers identified 398 patients who had 
undergone vascular access surgery for the first time for 
AVF creation between February 2007 and October 2010. 
Patients who underwent a repeat AVF creation (second 
and further fistula creations) were not included in the 
present study. Patients whose records contained incom-
plete information (n = 98) in relation to fistula outcomes 
were also excluded from the study. The data of the 300 
patients pinpointed for inclusion were obtained from 
patient medical records and surgery records; specifically, 
information on patient age, gender, and risk factors; 
peripheral vascular disease (PVD); diabetes mellitus; 
hypertension; smoking (ever versus never); and dialysis 
(ever versus never) was sourced. Patients were defined 
as obese when their BMI was > 30 kg/m2, consistent with 
the World Health Organization classification [9]. Fistula 
characteristics were ascertained, included fistula type 
and location (i.e., right or left). Clinically important bio-
medical factors including estimated glomerular filtration 
rate (eGFR), creatinine, blood urea, serum potassium, 
sodium, calcium, bicarbonate, prothrombin time (PT), 
international normalized ratio (INR), high-density lipo-
protein, triglycerides (TG), total cholesterol (TC), and 
vein diameter were also included in the analysis.
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Validation stage 
A total of 168 patients who had undergone surgery 
for AVF at the Royal Infirmary of Edinburgh between 
the years 2010 and 2012 were contacted for prospective 
clinical research. Out of the 168 patients contacted for 
this trial, 23 were unwilling to participate in this trial, 
10 dropped out during follow-up, and 35 were excluded 
from the study because they did not meet the inclusion 
and exclusion criteria. The most often cited reason for 
a patient not being willing to participate was personal 
commitments. Moreover, excluded patients included 
non-native English speakers (who were unable to give in-
formed consent) and those who had undergone a second 
attempt of AVF creation. Patients who had undergone a 
repeat AVF creation (second and further fistula creations) 
were not included in this study. Thus, a total of 100 pa-
tients were finally recruited into the prospective study. 
Written informed consent was obtained from the patients 
at the time of vascular imaging in the vascular lab at 
the Royal Infirmary of Edinburgh. Patients with current 
unstable angina or uncontrolled diabetes and a known 
bleeding disorder (i.e., bleeding diathesis) were excluded 
from the analysis. 
Duplex investigation of the veins was performed to 
measure the diameter of arm veins according to a stan-
dard protocol by vascular scientists in the vascular clinic 
of the Royal Infirmary of Edinburgh. All procedures 
such as general physical examination consisted of in-
spection and palpation of the vessels of the upper arm 
and forearm and measurement of brachial artery BP. 
Subsequently, height and weight details were recorded 
in order to calculate the BMI values and blood samples 
were obtained by the regular NHS staff. PVD was identi-
fied through a physical examination and by comparing 
the BP in the arm and ankle. An ankle-brachial pressure 
index value ≤ 0.90 reliably elucidates 95% of symptomatic 
arteriogram-positive PVD individuals and almost 100% 
of healthy controls [10].
Outcomes definition
Failure-to-mature fistula is defined as a fistula that has 
never matured so as to be useful, is difficult to cannulate, 
or that fails to generate the necessary blood flow (600 
mL/min) for a successful two-needle dialysis [8]. Matura-
tion was defined as the ability of AVF to be needled and 
provide ongoing functional hemodialysis at the sixth 
week [11,12] from the access procedure. An experienced 
dialysis specialist nurse determined when the fistula was 
ready for an attempt at cannulation and then attempted 
initial cannulation of the fistula; if unsuccessful, the fis-
tula was further evaluated by the vascular surgeon at the 
Royal Infirmary of Edinburgh.
Statistical analysis
Statistical analysis was performed using the SPSS Sta-
tistics version 22.0 (IBM Co., Armonk, NY, USA) and 
Stata version 9 (StataCorp LLC, College Station, TX, USA) 
software. Data were expressed as the mean, standard 
deviation, and 95% confidence interval (CI) or as the pro-
portion. A chi-squared test and t test were used for the 
comparison of independent variables between previous 
retrospective and prospective patients, while a P value of 
< 0.05 was considered to be statistically significant.
Development stage: The association between the inde-
pendent factors and outcome (i.e., mature fistula) was 
assessed by employing univariable logistic regression. 
Following the univariable associations, a multivariable 
model was produced utilizing backward stepwise logistic 
regression with those variables found to be significant 
in the univariable regression at P < 0.25. The odds ra-
tios (ORs) and associated 95% CIs for variables in the 
final model were reported. The significance level for this 
model was set at P < 0.05. We evaluated the calibration 
and discrimination performance of the model. For the 
calibration, the Hosmer-Lemeshow test was employed 
to investigate how well the predicted probabilities agreed 
with the observed probabilities. Discrimination, which 
refers to the ability of a model to distinguish between the 
maturation and immaturation of the AVF, was quantified 
using a receiver operating characteristic (ROC) curve. 
The ROC curve plots the sensitivity (true positive rate) 
against specificity (false positive rate) for consecutive 
“cutoffs” for the probability of an outcome [13].
Validation stage: A model precisely predicting the prob-
abilities for patients in the retrospective data would not 
guarantee accurate predictions for new patients from 
related populations, e.g., patients treated not long ago 
or patients from a different center; therefore, the perfor-
mance of prognostic models needed to be verified in the 
Kidney Res Clin Pract   Vol. 37, No. 3, September 2018
280 www.krcp-ksn.org
newly treated patient group (via external validation) [14]. 
Predictive logistic regression models are important tools 
to provide estimates of patient outcome probabilities [15]. 
We performed external validation on a different dataset 
obtained from an independent set of consecutive pa-
tients who had undergone vascular access surgery using 
the final development model. Validation performed on 
heterogeneous external datasets allows for the evaluation 
of the generalizability of the risk prediction tool to wider 
populations than originally reported. Predicted prob-
abilities for individual patients in the validation set were 
calculated. Model discrimination was assessed by ROC 
curve analysis. An evaluation of calibration is important if 
model predictions are used for making clinical decisions. 
A calibration plot formed by the Hosmer-Lemeshow test, 
which illustrates how the observed and expected propor-
tions compare, assessed the calibration of the final model 
for the maturation of the fistula. We plotted the observed 
outcome frequencies by decile of predicted probabilities. 
Results
A total of 400 patients were recruited for this study, with 
mean ages of 60 ± 15.7 years (immature AVF group) and 
60.45 ± 15.2 years (mature AVF group) (P = 0.77). The 
significant difference between the mature and immature 
AVF groups was evaluated against P < 0.05. Baseline ex-
ploration of patients’ characteristics discovered the two 
variables to be significantly different in both the mature 
and immature AVF cohorts. Patients with mature AVF 
were more frequently male as compared with the pa-
tients with immature AVF. The percentage of diabetics 
and those with PVD were higher in the immature AVF 
group. A significant difference (P = 0.002) was observed 
regarding PVD occurrence between the mature and im-
mature AVF groups. However, no statistically significant 
difference (P = 0.53) was observed with respect to dia-
betes. The percentage of hypertensive patients, patients 
with a history of prior hemodialysis therapy, mean PT, 
and TC were also not statistically different between the 
mature and immature AVF groups. Overall, both cohorts’ 
participant characteristics were similar. Clinical and de-
mographic characteristics of patients with mature and 
immature AVF are shown in Table 1.
Univariable associations
Univariable analysis found nine variables associated 
with the maturation of AVF: gender, side of arm, type of 
fistulas, PVD, diabetes, systolic BP, INR, TG, and vein size 
(Table 2). In addition to the above variables, a further two 
statistically nonsignificant variables, i.e., dialysis [16,17] 
(ever versus never) and eGFR [18] were added to the 
model due to their possible clinical association with the 
maturation of AVF as suggested by vascular surgeons.
Table 1. Summary of the baseline characteristics of indepen-
dent variables (n = 400)
Characteristic
Mature AVF  
(n = 228)
Immature AVF  
(n = 172)
P value
Gender (male/female) 68/32 59.3/40.7 0.07
Arm (left/right) 65.4/34.6 76.2/23.8 0.02*
DM (yes/no) 34.2/65.8 37.2/62.8 0.53
HTN (yes/no) 76.8/23.2 72.2/27.3 0.35
PVD (yes/no) 10.1/89.9 21.5/78.5 0.002*
Smoker (yes/no) 14/86 12.8/87.2 0.72
Dialysis prior to surgery 
(yes/no)
39.5/60.5 42.4/57.6 0.55
Type of AVF (BC/RC/BB) 70.2/22.8/7.0 58.1/28.5/13.4 0.02*
BMI (kg/m2) 26.5 ± 10.4 26.7 ± 8.9 0.81
Urea (mmol/L) 17.5 ± 9.0 17.3 ± 8.4 0.85
Creatinine (µmol/L) 414 ± 181 414.6 ± 187 0.98
eGFR (mL/min/1.73 m2) 14.1 ± 6.3 14.7 ± 7.4 0.48
K (mmol/L) 4.4 ± 0.8 4.5 ± 0.8 0.90
Na (mmol/L) 138.7 ± 3.8 138.8 ± 3.7 0.76
Ca (mmol/L) 2.3 ± 0.2 2.3 ± 0.2 0.59
HCO3 (mmol/L) 24.9 ± 5.0 24.7 ± 5.1 0.69
PT (sec) 10.8 ± 4.0 10.6 ± 3.6 0.61
INR (ratio) 1.04 ± 0.3 1.06 ± 0.4 0.47
TC (mmol/L) 4.2 ± 1.5 4.3 ± 1.4 0.78
TG (mmol/L) 2.2 ± 1.6 3.5 ± 1.6 0.31
HDL (mmol/L) 1.1 ± 0.4 1.8 ± 1.1 0.21
Vein size (mm) 3.6 ± 1.2 3.4 ± 1.02 0.08
Data are presented as number or mean ± standard deviation.
AVF, arteriovenous fistula; BB, brachiocephalic; BC, brachiocephalic; BMI, body 
mass index; Ca, calcium; DM, diabetes mellitus; eGFR, estimated glomerular 
filtra tion rate; HCO3, bicarbonate; HDL, high-density lipoprotein; HTN, hyper-
ten sion; INR, international normalization ratio; K, potassium; Na, sodium; PT, 
pro throm bin time; PVD, peripheral vascular disease; RC, radiocephalic; TC, total 
cholesterol; TG, triglyceride.
*Significant difference between two cohorts P < 0.05.
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Table 2. Univariable analysis of independent characteristics in the maturation of AVF
Factor Crude OR (95% CI) P value Factor Crude OR (95% CI) P value
Age (yr) 0.45 HCO3 (mmol/L) 0.743
   > 50    ≤ 23
   ≤ 50 0.814 (0.477-1.389)    > 23 0.926 (0.586-1.465)
Gender 0.049* Creatinine (μmol/L) 0.676
   Male    > 400
   Female 0.615 (0.379-0.998)    > 120 and ≤ 400 0.913 (0.576-1.447)
Arm 0.129*    ≤ 120 0.37 (0.033-4.182)
   Left Urea (mmol/L) 0.949
   Right 1.505 (0.887-2.553)    > 15 
Fistula 0.115*    > 6.6 and ≤ 15 1.076 (0.591-1.960)
   Brachiocephalic    ≤ 6.6 1.09 (0.73-2.073)
   Radiocephalic 0.715 (0.423-1.208) eGFR (mL/min/1.73 m2) 0.459
   Brachiocephalic 0.479 (0.222-1.036)    ≤ 15
Surgeons 0.788    > 15 0.834 (0.516-1.349)
   Surgeon A SBP (mmHg) 0.101*
   Surgeon B 0.985 (0.578-1.679)    ≤ 130
   Surgeon C 1.935 (0.367-10.206)    >130 1.468 (0.927-2.325)
   Surgeon D 0.516 (0.084-3.154) DBP (mmHg) 0.786
   Surgeon E 0.619 (0.162-2.373)    ≤ 85
Peripheral vascular disease 0.001*    > 85 0.897 (0.411-1.958)
   Yes BMI (kg/m2) 0.563
   No 3.04 (1.585-5.829)    ≤ 30
Diabetes mellitus 0.102*    > 30 1.165 (0.694-1.957)
   Yes PT (sec) 0.413
   No 1.48 (0.925-2.367)    ≤ 13.4
Smoker 0.49    > 13.5 0.757 (0.389-1.474)
   Yes INR (ratio) 0.140*
   No 0.789 (0.402-1.547)    ≤ 1.2
Hypertension 0.406    > 1.2 0.589 (0.292-1.189)
   Yes TC (mmol/L) 0.24*
   No 0.793 (0.458-1.371)    ≤ 5
Dialysis 0.513    >5 1.294 (0.804-2.084)
   Yes TG (mmol/L) 0.289
   No 1.17 (0.731-1.873)    ≤ 2.1
K+ (mmol/L) 0.948    > 2.1 0.773 (0.48-1.244)
   Normal HDL (mmol/L) 0.874
   Abnormal 1.015 (0.642-1.605)    ≤ 1.1
Na+ (mmol/L) 0.439    > 1.1 1.037 (0.658-1.637)
   Normal Vein size (mm) < 0.001*
   Abnormal 1.295 (0.673-2.494)    ≤ 2.5
Ca++ (mmol/L) 0.525    > 2.5 4.254 (1.983-9.126)
   ≤ 2.5
   > 2.5 0.804 (0.41-1.577)
AVF, arteriovenous fistula; BMI, body mass index; Ca, calcium; CI, confidence interval; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HCO3, 
bicarbonate; HDL, high-density lipoprotein; INR, international normalization ratio; K, potassium; Na, sodium; OR, odds ratio; PT, prothrombin time; SBP, systolic blood 
pressure; TC, total cholesterol; TG, triglyceride.
Independent patient factors and blood markers that underwent in univariate analysis and their association with the maturation of AVF; *significant variables having 
P < 0.25.
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Multivariable associations
Three variables were identified which were indepen-
dently associated with fistula maturation using multivari-
able logistic regression analysis (Table 3). Males were 
twice as likely to undergo fistula maturation as compared 
with females (OR, 0.514; 95% CI, 0.308-0.857; P = 0.011) 
and patients who had no evidence of PVD were three 
times more likely to mature their fistula (OR, 3.140; 95% 
CI, 1.596-6.177; P  < 0.001). Additionally, those with 
a preoperative vein diameter of greater than 2.5 mm 
showed a fivefold increase in fistula maturation versus 
those with a vein size of less than 2.5 mm (OR, 4.532; 95% 
CI, 2.063-9.958; P < 0.001). 
The performance of the final prognostic model assessed 
in terms of calibration using the Hosmer-Lemeshow 
test (which tests the null hypothesis that the model fits 
the data) was not significant (P = 0.79). This suggests that 
there was no statistically significant difference between 
the predicted and observed outcomes. The area under 
the ROC curve for the prediction of maturation of fistula 
was 0.68 (95% bias-corrected CI, 0.615-0.738), which in-
dicates fair [19] discrimination (Fig. 1). 
Model validation
We externally validated the development model, assess-
ing aspects of discrimination and calibration. The area 
under the ROC curve for the prediction of the maturation 
of fistula was calculated using predicted probabilities and 
patient outcomes (mature or immature) of each patient. 
The ROC area was 0.59 (95% bias-corrected CI, 0.471-
0.712) (Fig. 2). 
A better way of assessing the fit of a logistic regression 
model is compare the expected and observed numbers 
of positives for different subgroups of the data. If the 
observed and expected numbers are sufficiently close 
to one another, then we can assume that we have an ad-
equate model. The performance of the final prognostic 
model assessed in terms of calibration using Hosmer-
Lemeshow test was not significant (P > 0.05). This sug-
gests that there was no statistically significant difference 
between the predicted and observed outcomes.
Discussion
The long-term objective of the present research effort 
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Figure 1. Receiver operating characteristic (ROC) curve analy-
sis for the development of the prognostic model. It shows the 
ROCs of arteriovenous fistula (AVF) maturation. The area under the 
curve was 0.68 (95% bias-corrected confidence interval, 0.615-
0.738), indicating good discriminatory ability of AVF maturation. 
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Figure 2. Receiver operating characteristic (ROC) curve analy-
sis for validation of the prognostic model. It shows ROCs of 
arteriovenous fistula (AVF) maturation. The area under the curve 
was 0.591 (95% confidence interval, 0.471-0.712), indicating good 
discriminatory ability of AVF maturation. 
Table 3. Multivariable predictors of arteriovenous fistula 
maturation
Clinical characteristic Adjusted OR 95% CI P value
Gender (male) 0.514 0.308-0.857 0.011
PVD (no) 3.140 1.596-6.177 < 0.001
Vein size (> 2.5 mm) 4.532 2.063-9.958 < 0.001
CI, confidence interval; OR, odds ratio; PVD, peripheral vascular disease.
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was to identify factors predicting fistula maturation. We 
hypothesized that blood and patient characteristics could 
be used to stratify the risk of self-report of maturation of 
AVF. In brief, using the development dataset of 300 sub-
jects, we identified three variables associated with the 
maturation of fistula; gender, PVD, and vein size. These 
variables were validated by using the validation dataset 
of 100 subjects. 
Our study results showed a gender difference, with AVF 
maturation rates of 60% for men and 48% for women, 
respectively. Miller et al [20] found that AVF maturation 
is more successful in men than in women. Similar results 
were obtained by Iyem [21]. In our study, males were 
twice as likely to undergo fistula maturation as compared 
with females, with the most rational explanation for this 
difference being the smaller size of vessels in women. 
Some studies also found female gender to be associated 
with immature fistula [22]. However, in contrast, there are 
also studies that did not find a gender difference. Başer et 
al [23] evaluated the creation of AVFs in 114 participants 
and did not observe any gender difference in terms of the 
maturation of AVF.
Out of 300 patients, 38% were diabetic and 16% had 
clinical evidence of PVD. In a number of studies, it has 
been reported that more than 50% of North American di-
alysis patients have diabetes and approximately one-third 
have PVD [24,25]. In our study, fistula maturation oc-
curred at rates of 59.7% in patients with no history of PVD 
and 33.3% in patients with PVD. As such, this emerged as 
one of the predictive factors in the maturation of fistula 
in the multivariable analysis. Patients with no evidence 
of PVD were three times more likely to mature their fis-
tula. Our data are consistent with those of other studies 
in which PVD was associated with AVF failure [26]. Chan 
et al [27] conducted a retrospective cohort analysis using 
1,486 patients’ data. It was revealed that patients who suf-
fer from PVD are more likely to experience nonmatura-
tion of their AVFs (OR, 2.78; 95% CI, 1.01-7.63; P = 0.047). 
Fistula failure is consistent with the underlying need for 
adequate arterial vessels, which deteriorate with the nor-
mal aging process and can be damaged by concurrent 
disease; this finding is supported by other studies [20,28]. 
A recent single-center, retrospective chart review was 
performed by Bashar et al [29] to explore any possible 
association between preoperative hematological inves-
tigation and the functional maturation of AVF. A total of 
86 patients (with 97 AVFs) were recruited and univariate 
analysis showed that female gender had a significant as-
sociation with the nonmaturation of AVF. However, the 
study’s results did not find any association between PVD 
and AVF maturation. The smaller sample size as well as 
different study population and AVF maturation definition 
(functional maturation was defined as the successful use 
of the AVF for six consecutive sessions of hemodialysis) 
may have obscured this association in this investigation.
Our data are consistent with those of other studies in 
terms of which vein size was associated with the success-
ful maturation of fistulas. Mendes et al [30] reported that, 
when the diameter of the cephalic veins exceeded 2 mm, 
then there was a 76% success rate of functional dialysis 
access, whereas, if the diameter was less than 2 mm, then 
there was only a 16% success rate. In the present study, 
a preoperative vein diameter of greater than 2.5 mm re-
sulted in a fivefold increase in fistula maturation as com-
pared with a vein size of less than 2.5 mm. In this regard, 
our data are in correlation with those of other studies in 
terms of which vein size is associated with successful fis-
tula maturation [31]. The cutoff value identified by Brim-
ble et al [32] was 2.6 mm; however, only women exhibited 
a substantial discrepancy between AVF success and fail-
ure with regard to vein diameter. In contrast, Wong et al 
[33] did not observe any discrepancies between AVF suc-
cess and failure with respect to the mean vein diameter 
at the wrist, but indicated that AVF failure occurred in all 
cases where the vein diameter was less than 1.6 mm.
In research, the efficiency of a predictive model has to 
be tested on a new group of subjects. In the present case, 
the performance of the predictive model with regard to 
the external verification of fistulas that was constructed 
in the same hospital was good. The purpose of a predic-
tive model is to assess potential risks and to manage 
treatment accordingly so as to ensure the success of the 
AVF construction procedure. This practice can help to 
structure the process, ensure the efficient management 
of resource distribution, and limit expenses. The perfor-
mance of the developed model in this study was assessed 
by the discrimination and calibration of the model. The 
area under the ROC curve for a prognostic model is clas-
sically between 0.6 and 0.85 [34]. In our study, the ROC 
curve was primarily designed for prognostic models, 
rather than for diagnostic models. The ROC curve was 
0.68 in the development stage and 0.59 in the validation 
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stage, meaning that the model had a reasonable capacity 
to correctly distinguish between mature and immature 
fistulas. For clinical practice, providing insight beyond 
the concordance statistic has been a motivation for some 
recent measures, especially in the context of extension of 
a prediction model with additional predictive informa-
tion from a biomarker or other sources [24,25]. Accuracy 
of the model was assessed by examining calibration [35]. 
To assess the validity of the predictive model developed 
using the development dataset, we applied the model to 
an independent or validation dataset composed of 100 
subjects. There was excellent agreement between the 
predicted and observed percentages in predicting the 
maturation of AVF. We further note that a substantial size 
will be required for a validation sample to quantify valid-
ity in a reliable way, i.e., with enough power to prompt a 
substantial decrease in discriminative ability [36].
The present study has a number of limitations. The 
connection between artery diameter and blood inflow 
rate has been emphasized by a number of studies [31,37]. 
However, we did not include markers in our study due to 
the unavailability of retrospective data. Another limita-
tion of this study was the considerable discrepancies in 
the measurements of vessel diameter in the same indi-
vidual and between sonographers. Despite the effort put 
into monitoring every potential source of inconsistency, 
interobserver discrepancies in the patient sample were 
largely disregarded. Published studies describe hyper-
parathyroidism as an independent risk factor for vascular 
access thrombosis, probably induced by microcalcifica-
tion of the vessel wall [38]; however, due to unavailability 
of retrospective data, we did not include these variables 
in the present study. Further investigations are necessary 
to clarify a potential relationship between hyperparathy-
roidism and vascular access patency. Recent studies have 
also suggested an important role of matrix metallopro-
teinase in the process of AVF maturation [39]. A promis-
ing biomarker identified in human vein tissue, matrix 
metalloproteinase-2, may serve to predict AVF matura-
tion [40]. We did not look at matrix metalloproteinase as 
a predicative marker in the present study, however.
In summary, a preoperative, clinical prediction rule to 
determine fistulae that are likely to mature was created 
based on single-center analyzable datasets in AVF cre-
ation. Gender, PVD, and vein size are useful predictors 
of AVF maturation. The developed model was validated 
using the validation dataset. The clinical utility of these 
risk categories in the maturation of AVF requires further 
clinical evaluation in longer follow-up periods with the 
inclusion of additional variables such as diameter and 
blood flow of arteries. This could be done in the context 
of larger multicenter trials where treatment, follow-up, 
and endpoints are predefined and measured according 
to identical criteria in all patients.
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